These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20738251)

  • 1. Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer.
    Jiao J; Xiang H; Liao Q
    Curr Med Chem; 2010; 17(30):3476-87. PubMed ID: 20738251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress in study of the structure, catalytic mechanism and inhibitors of aromatase].
    Fu J; Shen ZH; Cheng FX; Liu GX; Li WH; Tang Y
    Yao Xue Xue Bao; 2012 Jan; 47(1):18-28. PubMed ID: 22493800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibitors for breast cancer in postmenopausal women.
    Campos SM
    Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibition: translation into a successful therapeutic approach.
    Geisler J; Lønning PE
    Clin Cancer Res; 2005 Apr; 11(8):2809-21. PubMed ID: 15837728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal aromatase inhibitors for the treatment of breast cancer: an update.
    Gobbi S; Rampa A; Belluti F; Bisi A
    Anticancer Agents Med Chem; 2014 Jan; 14(1):54-65. PubMed ID: 23869785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview.
    Ratre P; Kulkarni S; Das S; Liang C; Mishra PK; Thareja S
    Med Oncol; 2022 Dec; 40(1):41. PubMed ID: 36471176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
    Ahmad I; Shagufta
    Eur J Med Chem; 2015 Sep; 102():375-86. PubMed ID: 26301554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors and their application in breast cancer treatment*.
    Brodie AM; Njar VC
    Steroids; 2000 Apr; 65(4):171-9. PubMed ID: 10713305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding features of steroidal and nonsteroidal inhibitors.
    Hong Y; Rashid R; Chen S
    Steroids; 2011 Jul; 76(8):802-6. PubMed ID: 21420422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of aromatase inhibitors in breast cancer.
    Mokbel K
    Int J Clin Oncol; 2002 Oct; 7(5):279-83. PubMed ID: 12402060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of aromatase inhibitors and their pharmacologic profile.
    Lønning PE; Geisler J; Bhatnager A
    Am J Clin Oncol; 2003 Aug; 26(4):S3-8. PubMed ID: 12902871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
    Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letrozole for the management of breast cancer.
    Goss PE; Smith RE
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):249-60. PubMed ID: 12113048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch.
    Ratre P; Mishra K; Dubey A; Vyas A; Jain A; Thareja S
    Anticancer Agents Med Chem; 2020; 20(17):1994-2004. PubMed ID: 32593281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA; Lebwohl D
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
    Scott LJ; Keam SJ
    Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
    Lamb HM; Adkins JC
    Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.